Literature DB >> 17043021

The expression of PRDI-BF1 beta isoform in multiple myeloma plasma cells.

Esther Ocaña, Inés González-García, Norma C Gutiérrez, Francisco Mora-López, José A Brieva, Antonio Campos-Caro.   

Abstract

The PRDM1 gene, a master regulator of plasma cells (PC), can generate two transcription factor isoforms: PRDI-BF1alpha and PRDI-BF1beta. The present study shows that purified human normal PC have a significantly lower levels of PRDI-BF1beta expression than that in tumoral PC isolated from multiple myeloma (MM) (0.06+/-0.01 and 0.25+/-0.05, respectively; p<0.001). The role of this finding in MM is discussed.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17043021

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  4 in total

1.  PRDM1 is required for mantle cell lymphoma response to bortezomib.

Authors:  Shruti Desai; Michelle Maurin; Matthew A Smith; Sophia C E Bolick; Sophie Dessureault; Jianguo Tao; Eduardo Sotomayor; Kenneth L Wright
Journal:  Mol Cancer Res       Date:  2010-06-08       Impact factor: 5.852

2.  Hypomethylation and Over-Expression of the Beta Isoform of BLIMP1 is Induced by Epstein-Barr Virus Infection of B Cells; Potential Implications for the Pathogenesis of EBV-Associated Lymphomas.

Authors:  Katerina Vrzalikova; Sarah Leonard; Yichao Fan; Andrew Bell; Martina Vockerodt; Patrik Flodr; Kenneth L Wright; Martin Rowe; Qian Tao; Paul G Murray
Journal:  Pathogens       Date:  2012-10-08

3.  PRDI-BF1 and PRDI-BF1P isoform expressions correlate with disease status in multiple myeloma patients.

Authors:  Gabriele Buda; Francesca Guerrini; Sara Galimberti; Enrico Orciuolo; Simone Pacini; Elisa Mazzantini; Mario Petrini
Journal:  Hematol Rep       Date:  2017-12-22

4.  Differential epigenetic regulation between the alternative promoters, PRDM1α and PRDM1β, of the tumour suppressor gene PRDM1 in human multiple myeloma cells.

Authors:  Raquel Romero-García; Laura Gómez-Jaramillo; Rosa María Mateos; Gema Jiménez-Gómez; Nuria Pedreño-Horrillo; Esther Foncubierta; Juan Francisco Rodríguez-Gutiérrez; Sebastián Garzón; Francisco Mora-López; Carmen Rodríguez; Luis M Valor; Antonio Campos-Caro
Journal:  Sci Rep       Date:  2020-09-28       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.